Compare MRCC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCC | CRBP |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 134.8M |
| IPO Year | 2011 | 2014 |
| Metric | MRCC | CRBP |
|---|---|---|
| Price | $5.90 | $7.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $8.00 | ★ $50.29 |
| AVG Volume (30 Days) | 90.1K | ★ 138.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | ★ 2150.00 | 64.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $220.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $5.86 | $4.64 |
| 52 Week High | $8.85 | $20.56 |
| Indicator | MRCC | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 43.45 |
| Support Level | N/A | $6.73 |
| Resistance Level | $6.77 | $8.43 |
| Average True Range (ATR) | 0.18 | 0.47 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 10.75 | 38.50 |
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.